Day One Biopharmaceuticals reports Q4 EPS ($1.02), consensus (35c)

Reports Q4 revenue $29.M , consensus $27.79M. Achieved Q4 2024 and full year 2024 OJEMDA or tovorafenib, net product revenues of $29.M and $57.2M , respectively Ended 2024 with $531.7 million in cash, cash equivalents and short-term investments…”The approval of OJEMDA was the catalyst for our next stage of growth and I am proud that our team was able to offer OJEMDA to so many relapsed or refractory pediatric low-grade glioma (pLGG) patients in our first months of launch,” said Jeremy Bender, Ph.D., chief executive officer of Day One. “With OJEMDA as our foundation and a strong balance sheet, we believe we are on a path to long-term, durable growth and to the realization of Day One’s mission.”